Hero image

Research & products

We run to, not from, the world’s biggest health challenges.

The journey to invention and discovery is guided by science – and inspired by patients

Our purpose is to save and improve lives for generations. Our strategy is simple: We follow the science. The path to discovery is often unclear, but we are tireless in seeking solutions for some of the world’s most difficult health challenges.

Our work in numbers


people employed in research and development


people reached through our major programs and partnerships


invested in R&D in 2019

We address the world’s most difficult health challenges, following world-class science

Discovery & development

Step inside Merck Research Laboratories (MRL) where our quest to save and improve lives through research and development begins

B5 - Our pipeline__

We’re focused on inventing new medicines and vaccines to help more people

B5 we work to deliver

Our focus on breakthrough science is working

Clinical trials

Our progress is due in large part to the important and tough scientific questions we set out to answer with our trials and collaborations. We are grateful to the thousands of volunteers who participate in our clinical trials – making this all possible.

Father playing with young son at breakfast table

Our commitment to patients is unwavering

As long as there are still patients in hospitals, doctors and nurses desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here, fighting with all we have to deliver more, sooner.

Invention begins here

Our scientists are applying the latest groundbreaking research technologies and revolutionizing how we discover and develop medicines and vaccines

View our stories

Our new London Discovery Research Center site

The $1.32 billion, 220,000-square-foot research facility will be located in London’s “Knowledge Quarter”

Read more

Next: Our new London Discovery Research Center site

2Q 2020 Financial results

Merck announced second-quarter worldwide sales of $10.9 billion – a decrease of 8% compared with the second quarter of 2019 – reflecting the negative impact of COVID-19. Excluding the impact from foreign exchange, sales declined 5%. ​ The company anticipates full-year 2020 revenue range to be between $47.2 billion and $48.7 billion, including a negative […]

Read more

Next: 2Q 2020 Financial results

Lessons from dual pandemics

A conversation with Merck Chief Patient Officer Julie Gerberding, M.D., M.P.H., about her early work caring for people with HIV and AIDS, and the parallels of the AIDS and COVID-19 pandemics

Read more

Next: Lessons from dual pandemics

No patient left behind in our clinical trials

We’re here for patients when they need us most

Read more

Next: No patient left behind in our clinical trials

If you build it (in 3D), they will come

Innovating with the power of 3D printing

Read more

Next: If you build it (in 3D), they will come